2026-05-18 β€’ Breaking Convention (Substack)

Thank You!

and the official group photo!

External link. We are not responsible for the content.

Read more β†—

More From Breaking Convention (Substack)

2026-05-15 β€’ Breaking Convention (Substack)

Breaking Convention 2026 is here!

info for the day...

2026-05-13 β€’ Breaking Convention (Substack)

Official Schedule Out Now!

Plus limited edition t-shirt announcement!

2026-05-04 β€’ Breaking Convention (Substack)

Tickets running low!

plus more sessions announced and other events in London...

Latest News

2026-05-20 β€’ DoubleBlind Magazine

What Happens When You Feel Like Jesus After Taking Psychedelics?

Experts explain why some psychedelic trips end in claims of divinity β€” and when it becomes a problem. [...] Read More...

2026-05-20 β€’ OPEN Foundation

Truffles, therapy, disciplinary law – An OPEN perspective on the grey area in which (licensed) therapists operate in the Netherlands with regard to psychedelics

Read this article in Dutch here. On May 8, 2026, the Amsterdam Healthcare Disciplinary Board ruled on a significant c...

Policy
2026-05-19 β€’ Microdosing Institute

LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial

Repeated microdosing of LSD (8 to 20 ΞΌg) may help improve daily mood, specifically increasing feelings of connection,...

Microdosing Research
2026-05-19 β€’ Microdosing Institute

It’s all about the relationship: The caregiver experience of supporting a person with advanced cancer going through an LSD microdosing trial

Caregivers of people with advanced cancer often find that psychedelic-assisted therapy can strengthen their relations...

Microdosing Research
2026-05-19 β€’ Microdosing Institute

Epidemiology of Hallucinogen Microdosing Among Young Adults in the United States: A National Study

About 1 in 15 young adults in the United States reported microdosing hallucinogens in the past year.

Microdosing Research
2026-05-19 β€’ Microdosing Institute

Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial

Low doses of psilocybin may reduce the frequency of migraine attacks, but a two-dose "pulsed" schedule did not show a...

Microdosing Research